3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
10
Endometrial Neoplasms
6
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Paget's Disease, Mammary
1
Neoplasms by Site
1
Hereditary Sensory and Autonomic Neuropathies
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Endometrial Hyperplasia
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Advanced, Persistent, or Recurrent Endometrial Cancer
1
Interventions
Fulvestrant
3
cobimetinib
2
anlotinib
2
Bevacizumab
2
trametinib
1
selinexor
1
ribociclib
1
relacorilant
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
nintedanib
1
exemestane
1
enzalutamide
1
dabrafenib
1
atezolizumab
1
alectinib
1
abemaciclib
1
Watchful Waiting
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Trabectedin
1
Tamoxifen
1
STX-478
1
Pregnancy Tests
1
Pemetrexed
1
Metformin
1
Letrozole
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Tamoxifen
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled